Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by PutinKhuylo1on Sep 19, 2019 5:09pm

154 Views

Post# 30145237

RE:RE:RE:RE:RE:RE:RE:RE:Stock looks weak

Their lightening regimen, featuring 2% Hydroquinone, is going for US$195.00 a pop. R+F is a $2 billion annual revenue outfit. If skin lightening is 5% of their product revenue, annual sales would come in at about $100,000,000 or about 500,000 units of the lightening regimen. Figure out the rest.

Bullboard Posts

A Look into the Future of Chronic Pain Management